Michael Sacerdote
Biotech

Prana: Expect Success In Massive Binary Event

Executive summary:

  • Prana is an Australian biotech with a potential treatment for Alzheimer's disease.
  • Potential future revenues of at least $5 billion, but market cap is only $295 million.
  • Lead compound backed by spectacularly good science.
  • Imminent catalyst: results from Phase 2b IMAGINE trial due in March.
  • Conservative pre-result risk-adjusted net present value is at least $9.60/share.

_________________________________

Prana Biotechnology Limited (NASDAQ:PRAN) is a tiny clinical-stage company nearing completion of a pivotal Phase 2b trial of its compound PBT2 for the treatment of Alzheimer's disease. The company has also completed a Phase 2 study of PBT2 for the treatment of Huntington's disease, with results due at any time. The company's price history has been volatile to say the

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details